Tests whether adults with obesity or overweight can self-inject maridebart cafraglutide at home
Tests home self-injection of maridebart cafraglutide in adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
Key facts
- Where
- San Juan, Puerto RicoSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07871409, who can take part
Where in Puerto Rico
- Latin Clinical Trial CenterSan Juan, Puerto RicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amgen
- Trial code
- NCT07871409
- Record updated
- 9 November 2026
- Original description
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.Read full original descriptionShow less
A Phase 3 Multicenter, Open-label, Single-arm Trial Evaluating Home Self-Administration of Subcutaneous Maridebart Cafraglutide Via Autoinjector in Adult Participants Living With Obesity or Overweight Without Type 2 Diabetes Mellitus
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
Inclusion: Body mass index (BMI) ≥ 30 kilograms per meter square (kg/m\^2), or BMI ≥ 27 to < 30 kg/m\^2 with one of the following:; hypertension: treated, or with systolic blood pressure ≥ 130 millimeters of mercury (mmHg) or diastolic blood pressure ≥ 80 mmHg; dyslipidemia: treated or previously diagnosed high cholesterol, high triglycerides, or low HDL cholesterol; history of obstructive sleep apnea; history of cardiovascular disease; history of fatty liver disease (including metabolic dysfunction-associated steatotic liver disease [MASLD] or metabolic dysfunction-associated steatohepatitis [MASH]); At least 1 unsuccessful attempt at weight loss by diet and exercise; Contraception for females; Willingness to follow trial procedures for the duration of the trial.
Exclusion: Previous or planned surgical, endoscopic, or device-based treatment for obesity; Previous participation in a Maridebart Cafraglutide trial; Obesity induced by other endocrinologic disorders; History of malignancy within the past 5 years; Type 1 or Type 2 diabetes mellitus; History of chronic pancreatitis or history of acute pancreatitis within last 180 days; Family or personal history of medullary thyroid cancer; Change in body weight > 5 kg within last 90 days.